新功能、新界面、新体验,扫描即可下载竞博杯亚洲大师赛积分谷APP!
首页 » 投资 » 谁是竞博杯亚洲大师赛积分医药产业大金主?!盘点投资竞博杯亚洲大师赛积分医药产业最多的20家风投公司

谁是竞博杯亚洲大师赛积分医药产业大金主?!盘点投资竞博杯亚洲大师赛积分医药产业最多的20家风投公司

来源:竞博杯亚洲大师赛积分谷 2014-12-04 09:02

2014年12月2日讯 /竞博杯亚洲大师赛积分谷BIOON/ --随着竞博杯亚洲大师赛积分医药产业的飞速发展,许多投资者纷纷看中这一领域中的无限商机将大量资金都投入其中。可以说一种新药的问世,除了得益于科学家们日复一日的辛勤研究外,充足的资金也为其提供了最为坚强的后盾。甚至有人统计,一种新药的上市成本平均为数十亿美元之多。(相关阅读:危言耸听还是不差钱?塔夫茨药物开发研究中心宣称药物平均开发成本达到29亿美元!)不过新药一旦上市后,则会带给投资者以成倍的回报。而今天,竞博杯亚洲大师赛积分谷君编译汇总了2014年在竞博杯亚洲大师赛积分医药领域投资最多的20家风投公司。这二十家投资公司2014年在竞博杯亚洲大师赛积分医药领域的投资平均达到了12.5亿美元,而2013年这一数字为11亿美元。

同时,我们从这一榜单中也能发掘出许多有价值的信息。比如说榜单中许多风投公司都历史悠久,成立时间几乎都超过了20年,甚至排名第六的Bessemer Venture Partners公司历史可以追溯至1911年。表明竞博杯亚洲大师赛积分医药产业的光明前景都已经被大众所认同。

这些公司的分布主要集中于美国,除了风投公司传统聚集的纽约市,相当一部分都在波士顿、旧金山这两个全美竞博杯亚洲大师赛积分医药产业最集中的地区设有办事处。这也表明风投公司希望直接接触到希望投资的竞博杯亚洲大师赛积分医药公司的第一手资料,以便确定投资对象。

在竞博杯亚洲大师赛积分医药产业中心设立分公司也表明这些公司已经将竞博杯亚洲大师赛积分医药产业投资作为公司业务最重要的一部分!不过,随着时间推移,竞博杯亚洲大师赛积分谷君认为这一趋势可能会有所改变。原因在于近年来随着专利悬崖的到来和各大竞博杯亚洲大师赛积分医药公司产业研发的全球化,竞博杯亚洲大师赛积分医药公司的分布已经不再仅仅局限于那几个地方,而是呈现全世界辐射式分布的规律,这也必将拓展竞博杯亚洲大师赛积分医药行业风险投资的市场,哪个公司能够抓住这个机遇,或许就能在这一前景无限的市场分得最大的一块蛋糕。

此外,翻阅这些风投公司的投资目标,我们很少看到像辉瑞、诺华这类的竞博杯亚洲大师赛积分医药巨无霸。一方面原因固然是这些公司有着充足的资金,另一方面则是这些投资公司看好这些中小型企业的创造力,希望在他们身上实现竞博杯亚洲大师赛积分医药产业的重大突破。

最后,在这份榜单中同样值得注意的是,有五家公司在中国的北京和上海都设有分公司,这是否意味着这些公司已经开始针对发展中国家市场特别是中国市场提前布局?这些都令人深思。

No.20 SV Life Sciences      http://www.svlsa.com/

办事处:波士顿、旧金山、伦敦

投资总额:19亿美元

成立时间:1993年

No.19 Alta Partners   http://www.altapartners.com/ 

办事处:旧金山

投资总额:20亿美元

成立时间:1993年

公司投资的目标包括了Kite Pharma等著名公司在内的数十家竞博杯亚洲大师赛积分医药公司。

No.16(并列)Third Security   http://www.thirdsecurity.com/

办事处:维吉尼亚州雷德福市、旧金山、佛洛里达州棕榈滩

投资总额:20亿美元以上

成立时间:1999年

No.16(并列)Mohr Davidow Ventures   http://mdv.com/

办事处:美国加州门洛帕克

投资总额:20亿美元以上

成立时间:1983年

No.16(并列)Frazier Healthcare   http://www.frazierhealthcare.com/

办事处:西雅图、美国加州门洛帕克

投资总额:20亿美元以上

成立时间:1991年

No.14(并列)Morgenthaler Ventures-Life Sciences Team

办事处:帕洛阿尔托、波士顿、博尔德

投资总额:25亿美元

成立时间:1968年

No.14(并列)Essex Woodlands Health Ventures

办事处:帕洛阿尔托、休斯顿、纽约、伦敦、上海

投资总额:25亿美元

成立时间:1985年

No.13 Venrock  www.venrock.com 

办事处:美国麻省坎布里奇市、纽约、 帕洛阿尔托

投资总额:26亿美元

成立时间:1969年

No.12 MPM Capital   http://www.mpmcapital.com/

办事处:波士顿、旧金山、 盖恩斯维尔

投资总额:26亿美元以上

成立时间:1996年

No.11 Domain Associates

办事处:普林斯顿、圣迭戈

投资总额:27亿美元以上

成立时间:1985年

No.10 InterWest Partners http://www.interwest.com/

办事处:门洛帕克

投资总额:28亿美元以上

成立时间:1979年

No.9 Atlas Venture  http://www.atlasventure.com/ 

办事处:坎布里奇

投资总额:30亿美元以上

成立时间:1980年

No.8 Index Ventures http://indexventures.com/

办事处:伦敦、日内瓦、旧金山、圣埃黎耶、日内瓦

投资总额:38亿美元

成立时间:1996年(前身为1976年建立的Index Securities)

No.7 Polaris Partners  http://www.polarispartners.com/

办事处:波士顿、沃尔瑟姆、旧金山、都柏林

投资总额:40亿美元

成立时间:1996年

No.6 Bessemer Venture Partners  http://www.bvp.com/

办事处:坎布里奇、纽约、门洛帕克、巴西圣保罗、印度班加罗尔

投资总额:40亿美元以上

成立时间:1911年

No.4 (并列) Highland Capital Partners  http://www.hcp.com/

办事处:坎布里奇、帕洛阿尔托、上海、伦敦、日内瓦

投资总额:42亿美元

成立时间:1988年

No.4 (并列) Canaan Partners  http://canaan.com/ 

办事处:门洛帕克、韦斯特波特、印度古尔冈、以色列荷兹利亚

投资总额:42亿美元

成立时间:1987年

No.3 Kleiner Perkins Caufield & Byers (KPCB)  http://www.kpcb.com/

办事处:门洛帕克、旧金山、北京、上海

投资总额:70亿美元

成立时间:1972年

No.2 OrbiMed Advisors http://www.orbimed.com/

办事处:纽约、旧金山、孟买、上海、以色列荷兹利亚

投资总额:120亿美元

成立时间:1989年

No.1 New Enterprise Associates (NEA) http://www.nea.com/

办事处:门洛帕克、蒂莫尼姆 、芝加哥、纽约、坎布里奇、北京、上海、印度班加罗尔、孟买

投资总额:140亿美元

成立时间:1977年

(竞博杯亚洲大师赛积分谷Bioon.com)

详细英文报道:

The stampede is back on among venture capital firms to raise new money and close more funds, after years of standing pat following the recession and years of sluggish recovery.

Polaris Partners became the latest VC firm in the money on November 24, when it announced it had closed on its $450 million seventh fund, to be focused on healthcare and technology investments. That seventh fund closed $50 million higher than the $400 million "offering amount" that the firm stated back on June 17, when it disclosed its plan to raise the fund in a Form D filing with the U.S. Securities and Exchange Commission.

Polaris isn't alone. Just last month, Canaan Partners closed on its $675 million tenth fund. Canaan and Polaris are two of nine firms on this year's List to have closed on new funds this year, raising among them a total $3.935 billion. Another six venture firms disclosed plans to raise new funds totaling an additional reported $2.78 billion; the actual number is undoubtedly higher, since one of those firms would not disclose a figure on its Form D.

So who else joined those firms in investing capital in biotechs this year? Below is this year's GEN list of 20 top venture capital firms, and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active "committed" capital from funds in use.

This year's list shows the upward progression of VC firms; the lowest-ranked of this year's firms had $1.25 billion under management, compared with more than $1.1 billion for the Top 30 Venture Capital Firms of 2013. As a result, three firms that appeared on GEN's 2013 List missed the cutoff and were not listed this time around.

The firms themselves are the sources of much of the information, though in some instances, amounts of capital under management were calculated by adding the value of newly closed funds with previously disclosed amounts. In a handful of instances, figures and facts came from biographies of the firms' principals available on the websites of investee companies and publicly available investor presentations posted online.

All non-U.S. currencies were converted into U.S. dollars on November 21-24.

#20. SV Life Sciences

City (cities) where offices are located: Boston; San Francisco; London

Fund size and status: Approximately $1.9 billion under management across five funds

Current fund: $524 million SV Life Sciences Fund V, closed 2010; fund includes $513 million, plus $11 million of co-investments committed by partners and individuals affiliated with SVLS

Current biopharma portfolio companies: Achillion Pharmaceuticals, Adimab, Affibody, Affinium Pharmaceuticals, Alba Therapeutics, Alinea Pharmaceuticals, AlloCure, Allos Therapeutics, Antiva, Archemix, Arsanis Biosciences, Atopix Therapeutics/Oxagen, Autifony Therapeutics, Auxilium, Avera Pharmaceuticals, Avitide, Axys, Bicycle Therapeutics, Calchan Holdings, Catabasis Pharmaceuticals, Cellzome, Convergence Pharmaceuticals, Coral Therapeutics, Cyterix Pharmaceuticals, Delenex Therapeutics, Dynogen Pharmaceuticals, EUSA Pharma, Good Start Genetics, Ikano Therapeutics, Imagen Biotech, Itero Biopharmaceuticals, Juvaris Biotherapeutics, KalVista Pharmaceuticals, Karus Therapeutics, Link Medicine, Logical Therapeutics, Lux Biosciences, Micromet, Mpex Pharmaceuticals, NeurogesX, Neurotech, NKT Therapeutics, Oncoethix, Ophthotech, PanOptica, Pulmocide, Rempex Pharmaceuticals, Shire Pharmaceuticals, Sutro Biopharma, Thesan Pharmaceuticals, TopiVert, Vantia Pharmaceuticals, VHsquared, X2-Pharma

Year established: Established 1993 as Schroder Ventures Life Sciences.

#19. Alta Partners

City (cities) where offices are located: San Francisco

Fund size and status: $2 billion under management across eight funds

Current fund: $500 million Alta Partners VIII, a first stage-independent life sciences fund closed 2006

Current biopharma portfolio companies: 7TM Pharma, Ablynx, AcelRx Pharmaceuticals, Achaogen, Aegerion Pharmaceuticals, Aerie Pharmaceuticals, Aerovance, Alba Therapeutics, Allakos, Applied Genetic Technologies, Astex Pharmaceuticals, aTyr Pharma, Azelon Pharmaceuticals, Cara Therapeutics, Ceregene, Cerenis Therapeutics, ChemoCentryx, Chimerix, Corcept Therapeutics, CymaBay Therapeutics, Cytokinetics, DiscoveRx, Esperion Therapeutics, Excaliard Pharmaceuticals, Genedata, Immune Design, Intarcia Therapeutics, Kiadis Pharma, Kite Pharma, Lumena Pharmaceuticals, MacroGenics, Neothetics, Nereus Pharmaceuticals, Pathwork Diagnostics, Portola Pharmaceuticals, Proacta Therapeutics, Prolacta Bioscience, SARcode Bioscience, Scynexis, Silence Therapeutics, Sonexa Therapeutics, Sunesis Pharmaceuticals, Sutro Biopharma, Threshold Pharmaceuticals, Trevena, Veloxis Pharmaceuticals, ViroBay, VitrOmics, Zafgen, ZS Pharma

Year established: 1996

#16 (tie). Third Security

City (cities) where offices are located: Radford, VA; San Francisco; Palm Beach, FL

Fund size and status: More than $2 billion under management through nine affiliated investment funds, consisting of seven New River Management Funds and two regional funds

Current New River Management Funds: $120 million New River Management VII, closed 2012; $15 million Valleys' Ventures, launched 2013 to invest in companies that intend to commence operations in, or are willing to relocate to an area within 100 miles of Montgomery, Roanoke or Botetourt counties of southwestern Virginia

Current biopharma portfolio companies: Agilis, AmpliPhi Biosciences, AveXis, Fibrocell Science, Halozyme Therapeutics, Intrexon, Oragenics, OvaScience, Soligenix, Synthetic Biologics

Year established: 1999

#16 (tie). Mohr Davidow Ventures

City (cities) where offices are located: Menlo Park, CA

Fund size and status: More than $2 billion under management in nine funds

Most recent fund: $670 million MDV IX fund, first closed 2007 at $580 million.(1)

Current biopharma portfolio companies: Adamas, Balance Therapeutics, CardioDx, Crescendo Bioscience, DVS Sciences, Pacific Biosciences, Personalis, RainDance Technologies, Sequenta

Year established: 1983

#16 (tie). Frazier Healthcare

City (cities) where offices are located: Seattle and Menlo Park, CA

Fund size and status: More than $2 billion under management across seven funds

Current fund: $377 million Frazier Healthcare VII, closed 2013

Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Cidara Therapeutics, Collegium Pharmaceutical, Portola Pharmaceuticals, QuatRx Pharmaceuticals, Rempex Pharmaceuticals, Semnur Pharmaceuticals, Silvergate Pharmaceuticals, Tobira Therapeutics, VentiRx Pharmaceuticals

Year established: 1991

#14 (tie). Morgenthaler Ventures-Life Sciences Team

City (cities) where offices are located: Palo Alto, CA; Boston; Boulder, CO

Fund size and status: More than $2.5 billion under management

Current fund: $400 million Fund IX, closed 2008 and used in part for investment in life-sciences companies. (3)(2)

Current biopharma portfolio companies: Calithera Biosciences, Catalyst Biosciences, Elcelyx Therapeutics, Galleon Pharmaceuticals, GlobeImmune, Mosaic Biosciences, NaZura, OncoMed Pharmaceuticals, Orexigen, Principia Biopharma, Promedior Pharmaceuticals, Ra Pharmaceuticals, Replidyne, Ribozyme Pharmaceuticals, Scioderm, Stemgent, Threshold Pharmaceutical, Tragara Pharmaceuticals, Trellis Bioscience, Vical

Year established: 1968

#14 (tie). Essex Woodlands Health Ventures

City (cities) where offices are located: Palo Alto, CA; Houston; New York; London; Shanghai

Fund size and status: More than $2.5 billion under management across eight funds (4)

Current fund: $900 million Fund VIII, closed 2009 (4)

Current biopharma portfolio companies: Acura Pharmaceuticals, Biotoscana, Bioventus, Catalyst Biosciences, Chroma Therapeutics, Corium, Curis, Echo Therapeutics, Elusys Therapeutics, Horizon Pharma, IntegenX, LightSciences Oncology, Medicinova, Molecular Partners, Open Monoclonal Technology, Oraya Therapeutics, Revance Therapeutics, Symphogen, Ziopharm Oncology

Year established: 1985

#13. Venrock

City (cities) where offices are located: Cambridge, MA; New York; Palo Alto, CA

Fund size and status: $2.6 billion under management across seven funds

Current funds: $450 million Venrock VII, closed July 2014 and intended to invest in technology and healthcare companies; $350 million Venrock VI, closed 2010 (5)

Current biopharma portfolio companies: Acceleron Pharma, Achaogen, Anacor Pharmaceuticals, Ariosa Diagnostics, Avalanche Biotech, AVEO Pharmaceuticals, Celladon, Cerulean, Constellation Pharmaceuticals, CymaBay Therapeutics, Fate Therapeutics, Hua Medicine, Infinity Pharmaceuticals, Intarcia Therapeutics, Ironwood Pharma, Juno Therapeutics, QuatRx Pharmaceuticals, Receptos, Vitae Pharmaceuticals

Year established: 1969

#12. MPM Capital

City (cities) where offices are located: Boston (6); South San Francisco, CA; Gainesville, FL; Munich

Fund size and status: More than $2.6 billion committed capital under management across five funds

Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010 (7)

Current biopharma portfolio companies: 23andMe, Amphivena Therapeutics, Anthera Pharmaceuticals, Aratana Therapeutics, Astute Medical, Celladon, Cerecor, Chiasma, Conatus Pharmaceuticals, Epizyme, Iconic Therapeutics, Mitokyne, Proteon Therapeutics, Radius Health, Rhythm Pharmaceuticals, SAI, Selexys Pharmaceuticals, Sideris Pharmaceuticals, Solasia Pharma, Syndax Pharmaceuticals, Theraclone Sciences, True North Therapeutics, Vascular Pharmaceuticals, Verastem

Year established: 1996

#11. Domain Associates

City (cities) where offices are located: Princeton, NJ, and San Diego

Fund size and status: More than $2.7 billion under management across eight funds

Current fund: $500 million Domain Partners VIII, closed 2009

Current biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Aldeyra Therapeutics, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, Atara Biotherapeutics, aTyr Pharma, BioNano Genomics, Cantex Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Dicerna Pharmaceuticals, Domain Elite Holdings, Domain Russia Investments, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Marinus Pharmaceuticals, Meritage Pharma, NovaDigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ProteinSimple, Regardo Biosciences, Sera Prognostics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix

Year established: 1985

#10. InterWest Partners

City (cities) where offices are located: Menlo Park, CA

Fund size and status: $2.8 billion under management across 10 funds

Current fund: $650 million InterWest Partners X, closed 2008

Current biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Arcion Therapeutics, Carbylan Therapeutics, Cebix, Centrexion, Cidara Therapeutics, Drais Pharmaceuticals, Eiger BioPharmaceuticals, Lycera, MacroGenics, Ocera Therapeutics, On Demand Therapeutics, Paratek Pharmaceuticals, PMV Pharma, QuatRx Pharmaceuticals, RadioRx, Tesaro, Trius Therapeutics, USDS, Xenon Pharmaceuticals

Year established: 1979

#9. Atlas Venture

City (cities) where offices are located: Cambridge, MA

Fund size and status: More than $3 billion in committed capital across nine funds.

Current fund: $265 million Atlas Venture IX, closed in 2013 (8)

Current biopharma portfolio companies: Annovation Biopharma, Arteaus Therapeutics, Ataxion, Bicycle Therapeutics, CoStim Pharmaceuticals, Egalet, F-star, Harbour Antibodies, Horizon Pharma, InfaCare Pharmaceutical, Lysosomal Therapeutics, MiRagen Therapeutics, Mnemosyne Pharmaceuticals, Navitor Pharmaceuticals, Nimbus Discovery, Numerate, Padlock Therapeutics, RaNA Therapeutics, Rodin Therapeutics, Spero Therapeutics, Synlogic, Vitae Pharmaceuticals, Zafgen

Year established: 1980

#8. Index Ventures

City (cities) where offices are located: London, Geneva, San Francisco, and St. Helier, Jersey

Fund size and status: $3.8 billion in total committed capital across mixed and dedicated funds, of which about $1 billion is dedicated to life sciences

Current fund: €150 million ($200 million) Index Life Sciences Fund with co-investment by GlaxoSmithKline and Johnson & Johnson, closed 2012; €400 million ($550 million) Index Ventures VII, closed June 11, which the firm said will make "seed and early-stage" investments in tech startups. (9)

Current biopharma portfolio companies: CoMentis, Egalet, Epsilon 3 Bio, FF Pharma, GenSight Biologics, GlycoVaxyn, Levicept, Minerva Neurosciences, Molecular Partners, Novocure, Oncoethix, Sequenta, Versartis, XO1

Year established: 1996; successor to Index Securities, founded 1976

#7. Polaris Partners

City (cities) where offices are located: Boston; Waltham, MA; San Francisco; Dublin; Also, @dogpatchlabs location in Dublin for biotechnology and technology startups

Fund size and status: About $4 billion under management across seven funds (10)

Current fund: $450 million Polaris Venture Partners VII, closed Nov. 24; firm says on its website it continues to invest its sixth fund, $375 million Polaris Venture Partners VI, closed 2010 (10)

Current biopharma portfolio companies: 480 Biomedical, Acceleron Pharma, Adimab, Advion, AgBiome, Alector, Alimera Sciences, Arsanis Biosciences, Arsenal Medical, aTyr Pharma, Cerulean Pharma, Editas, Fate Therapeutics, Genocea Biosciences, Hydra Biosciences, Ironwood, Kala Pharmaceuticals, KinDex Pharmaceuticals, Navitor Pharmaceuticals, NextCODE, Ocular Therapeutix, Promedior, Pulmatrix, Receptos, Scholar Rock, Selecta Biosciences, T2 Biosystems, Trevena, Visterra, Xtuit Pharmaceuticals

Year established: 1996

#6. Bessemer Venture Partners

City (cities) where offices are located: Cambridge, MA; New York; Menlo Park, CA; S?o Paulo, Brazil; Herzliya Pituach, Israel; Bangalore, India

Fund size and status: More than $4 billion under management across eight funds (11)

Current fund: $1.6 billion Bessemer Venture Partners VIII, closed 2011 (11)

Current biopharma portfolio companies: Acceleron Pharma, AffyMax, Allena Pharmaceuticals, Cerulean Pharma, Flex Pharma, On-Q-ity, OvaScience, Oxagen, Proteon Therapeutics, Transave Inhalation Biopharmaceuticals, Verastem

Year established: 1911

#4 (tie). Highland Capital Partners

City (cities) where offices are located: Cambridge, MA; Palo Alto, CA; Shanghai; London; and Geneva

Fund size and status: $4.2 billion under management across 12 funds. (12)

Current fund: €250 million ($310 million) Highland Capital Growth Fund, closed in May; and the $400 million Highland Capital Partners IX L.P., closed 2013

Current biopharma portfolio companies: Hyperion Therapeutics, OpGen,

Year established: 1988

#4 (tie). Canaan Partners

City (cities) where offices are located: Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel

Fund size and status: $4.2 billion under management across nine funds

Current fund: $675 million Canaan Partners X, announced Oct. 16

Current biopharma portfolio companies: Aldea Pharmaceuticals, Arvinas, Axial Exchange, Chimerix, Chrono Therapeutics, CytomX, Dermira, Durata Therapeutics, Envisia Therapeutics, LQ3 Pharma, Marinus Pharmaceuticals, Novira Therapeutics, Sample6, Semnur Pharmaceuticals, Spinifex Pharmaceuticals, Theraclone Sciences, Tobira Therapeutics, VaxInnate

Year established: 1987

#3. OrbiMed Advisors

City (cities) where offices are located: New York; San Francisco; Mumbai; Shanghai; Herzliya, Israel

Fund size and status: Approximately $12 billion under management in five public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to invest in healthcare royalty streams

Current fund: $325 million OrbiMed Asia Partners II, closed September; $735 million OrbiMed Private Investments V, closed October 2013

Current biopharma portfolio companies: Acceleron Pharma, Adaptimmune, Aerocrine, Adimab, Aerpio, Affimed, Alector, Amarin, Ambit Biosciences, Anthera, arGEN-X, ARMO BioSciences, Arsanis Biosciences, Arteaus, Audentes Therapeutics, Avitide, Bharat Serums and Vaccines, Biodel, BioLineRx, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Clementia, Dimension Therapeutics, Durata Therapeutics, Eddingpharm, GC-Rise Pharmaceutical, Good Start Genetics, Igenica, Intercept Pharmaceuticals, Invitae, Iroko Pharmaceuticals, Loxo Oncology, Mirati Therapeutics, Otic Pharma, Otonomy, OxOnc Development, PharmAbcine, Pieris, Principia Biopharma, ProNAi, RDD Pharma, RedHill Biopharma,  Relypsa, Response BioMedical, Roka BioScience, Sage Therapeutics, Selecta Biosciences, Shasun,  singulex, Symbionics Therapeutics, Waterstone Pharmaceuticals

Year established: 1989

#2. Kleiner Perkins Caufield & Byers (KPCB)

City (cities) where offices are located: Menlo Park, CA; San Francisco; Beijing; Shanghai

Fund size and status: More than $7 billion in assets under management across 19 funds (13)

Current fund: $525 million KPCB XV, closed 2012 (13)

Current biopharma portfolio companies:(14) ApniCure, Armo BioSciences, Atara Bio, Auxogyn, Crescendo Bioscience, Elcelyx, Epizyme, FivePrime Therapeutics, Focal, Foundation Medicine, Oculeve, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Practice Fusion, Rapid Micro Biosystems, Tesaro, True North Therapeutics

Year established: 1972

#1. New Enterprise Associates (NEA)

City (cities) where offices are located: Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, Chicago; Cambridge, MA; as well as affiliate operations in Beijing; Shanghai; Bangalore; Mumbai.

Fund size and status: More than $14 billion in committed capital across 14 funds

Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed 2012

Current biopharma portfolio companies: 3-V Biosciences, Acadia Pharmaceuticals, Adaptimmune, Alimera Sciences, Amicus Therapeutics, Ardelyx, Blend Therapeutics, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Cerecor, Cleave Biosciences, Clovis Oncology, Cydan, Dermira, Edimer Pharmaceuticals, Envisia Therapeutics, Epizyme, Galera Therapeutics, Glycomimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Intrinsic Therapeutics, Liquidia Technologies, Loxo Oncology, Lumos Pharma, Mersana Therapeutics, Mirna Therapeutics, Nexchem, NexImmune, Novast Holdings, Predictive Biosciences, Prosensa,  Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Roka Bioscience, Satori Pharmaceuticals, Sunesis Pharmaceuticals, Supernus Pharmaceuticals,  Targacept, Tesaro, Transcept Pharmaceuticals, Tracon Pharmaceuticals, Trevena, Zyngenia

Year established: 1977

 

温馨提示:87%用户都在竞博杯亚洲大师赛积分谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库